481 results on '"Derosa, Lisa"'
Search Results
2. Acyl-coenzyme a binding protein (ACBP) - a risk factor for cancer diagnosis and an inhibitor of immunosurveillance
3. Antibiotics are associated with worse outcomes in lung cancer patients treated with chemotherapy and immunotherapy
4. Influence of microbiota-associated metabolic reprogramming on clinical outcome in patients with melanoma from the randomized adjuvant dendritic cell-based MIND-DC trial
5. Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma
6. From mucosal infection to successful cancer immunotherapy
7. Correction: Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers
8. Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial
9. Custom scoring based on ecological topology of gut microbiota associated with cancer immunotherapy outcome
10. Melanoma and microbiota: Current understanding and future directions
11. Gut microbiome predicts gastrointestinal toxicity outcomes from chemoradiation therapy in patients with head and neck squamous cell carcinoma
12. Author Correction: Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial
13. Efficacy and Safety of Concomitant Proton Pump Inhibitor and Nivolumab in Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study
14. Benzodiazepines compromise the outcome of cancer immunotherapy.
15. Faecalibacterium prausnitzii strain EXL01 boosts efficacy of immune checkpoint inhibitors.
16. Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma
17. Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer
18. Prolonged SARS-CoV-2 RNA virus shedding and lymphopenia are hallmarks of COVID-19 in cancer patients with poor prognosis
19. Cross-tissue single-cell landscape of human monocytes and macrophages in health and disease
20. Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade
21. Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment
22. Multifaceted modes of action of the anticancer probiotic Enterococcus hirae
23. Addition of Primary Metastatic Site on Bone, Brain, and Liver to IMDC Criteria in Patients With Metastatic Renal Cell Carcinoma: A Validation Study
24. Influence of microbiota-associated metabolic reprogramming on clinical outcome in patients with melanoma from the randomized adjuvant dendritic cell-based MIND-DC trial
25. State of the art and the future of microbiome-based biomarkers:a multidisciplinary Delphi consensus
26. Physiologic colonic uptake of 18F-FDG on PET/CT is associated with clinical response and gut microbiome composition in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors
27. Characterizing the immune tumor microenvironment in ALK fusion-positive lung cancer: state-of-the-art and therapeutical implications.
28. Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19
29. Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients
30. On-target Toxicities Predictive of Survival in Metastatic Renal Cell Carcinoma (mRCC) Treated With Sunitinib: A Multicenter Retrospective Study
31. New pathways in immune stimulation: targeting OX40
32. The immuno-oncological challenge of COVID-19
33. Chemotherapy-induced ileal crypt apoptosis and the ileal microbiome shape immunosurveillance and prognosis of proximal colon cancer
34. PD-1 Blockade in Renal Cell Carcinoma
35. A probiotic supplement boosts response to cancer immunotherapy
36. Fecal microbiota transplantation: can it circumvent resistance to PD-1 blockade in melanoma?
37. 1510 Multiomic functional biomarkers for cancer prediction and early detection
38. Longitudinal gut microbiome changes in immune checkpoint blockade in advanced melanoma
39. Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
40. Les métastases cérébrales de cancer du rein, un défi clinique
41. Drug Holiday in Metastatic Renal-Cell Carcinoma Patients Treated With Vascular Endothelial Growth Factor Receptor Inhibitors
42. The impact of the intestinal microbiota in therapeutic responses against cancer
43. Anticorps monoclonaux en oncologie : déclencher une réponse immunitaire en plus de la réduction tumorale spécifique.
44. Therapeutic sequencing in the era of first-line immune checkpoint inhibitor combinations, a novel challenge in patients with metastatic clear-cell renal cell carcinoma
45. A new prognostic model for survival in second line for metastatic renal cell carcinoma: development and external validation
46. Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers
47. Immunodynamics of explanted human tumors for immuno‐oncology
48. Author Correction: The immuno-oncological challenge of COVID-19
49. Everolimus Versus Axitinib as Second-line Therapy in Metastatic Renal Cell Carcinoma: Experience From Institut Gustave Roussy
50. Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.